Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index; 4 of the 46 sources its claims cite were checked for support.

Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis

Open access
De Crescenzo, Franco, D'Alò, Gian Loreto, Ostinelli, Edoardo G, Ciabattini, Marco, Di Franco, Valeria, Watanabe, Norio, Kurtulmus, Ayse, Tomlinson, Anneka, Mitrova, Zuzana, Foti, Francesca, Del Giovane, Cinzia, Quested, Digby J, Cowen, Phil J, Barbui, Corrado, Amato, Laura, Efthimiou, Orestis, Cipriani, Andrea · 2022 · The Lancet

Abstract

BACKGROUND: Behavioural, cognitive, and pharmacological interventions can all be effective for insomnia. However, because of inadequate resources, medications are more frequently used worldwide. We aimed to estimate the comparative effectiveness of pharmacological treatments for the acute and long-term treatment of adults with insomnia disorder. METHODS: In this systematic review and network meta-analysis, we searched the Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, Embase, PsycINFO, WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, and websites of regulatory agencies from database inception to Nov 25, 2021, to identify published and unpublished randomised controlled trials. We included studies comparing pharmacological treatments or placebo as monotherapy for the treatment of adults (≥18 year) with insomnia disorder. We assessed the certainty of evidence using the confidence in network meta-analysis (CINeMA) framework. Primary outcomes were efficacy (ie, quality of sleep measured by any self-rated scale), treatment discontinuation for any reason and due to side-effects specifically, and safety (ie, number of patients with at least one adverse event) both for acute and long-term treatment. We estimated summary standardised mean differences (SMDs) and odds ratios (ORs) using pairwise and network meta-analysis with random effects. This study is registered with Open Science Framework, https://doi.org/10.17605/OSF.IO/PU4QJ. FINDINGS: We included 170 trials (36 interventions and 47 950 participants) in the systematic review and 154 double-blind, randomised controlled trials (30 interventions and 44 089 participants) were eligible for the network meta-analysis. In terms of acute treatment, benzodiazepines, doxylamine, eszopiclone, lemborexant, seltorexant, zolpidem, and zopiclone were more efficacious than placebo (SMD range: 0·36-0·83 [CINeMA estimates of certainty: high to moderate]). Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0·27-0·71 [moderate to very low]). Intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer discontinuations due to any cause than ramelteon (OR 0·72 [95% CI 0·52-0·99; moderate], 0·70 [0·51-0·95; moderate] and 0·71 [0·52-0·98; moderate], respectively). Zopiclone and zolpidem caused more dropouts due to adverse events than did placebo (zopiclone: OR 2·00 [95% CI 1·28-3·13; very low]; zolpidem: 1·79 [1·25-2·50; moderate]); and zopiclone caused more dropouts than did eszopiclone (OR 1·82 [95% CI 1·01-3·33; low]), daridorexant (3·45 [1·41-8·33; low), and suvorexant (3·13 [1·47-6·67; low]). For the number of individuals with side-effects at study endpoint, benzodiazepines, eszopiclone, zolpidem, and zopiclone were worse than placebo, doxepin, seltorexant, and zaleplon (OR range 1·27-2·78 [high to very low]). For long-term treatment, eszopiclone and lemborexant were more effective than placebo (eszopiclone: SMD 0·63 [95% CI 0·36-0·90; very low]; lemborexant: 0·41 [0·04-0·78; very low]) and eszopiclone was more effective than ramelteon (0.63 [0·16-1·10; very low]) and zolpidem (0·60 [0·00-1·20; very low]). Compared with ramelteon, eszopiclone and zolpidem had a lower rate of all-cause discontinuations (eszopiclone: OR 0·43 [95% CI 0·20-0·93; very low]; zolpidem: 0·43 [0·19-0·95; very low]); however, zolpidem was associated with a higher number of dropouts due to side-effects than placebo (OR 2·00 [95% CI 1·11-3·70; very low]). INTERPRETATION: Overall, eszopiclone and lemborexant had a favorable profile, but eszopiclone might cause substantial adverse events and safety data on lemborexant were inconclusive. Doxepin, seltorexant, and zaleplon were well tolerated, but data on efficacy and other important outcomes were scarce and do not allow firm conclusions. Many licensed drugs (including benzodiazepines, daridorexant, suvorexant, and trazodone) can be effective in the acute treatment of insomnia but are associated with poor tolerability, or information about long-term effects is not available. Melatonin, ramelteon, and non-licensed drugs did not show overall material benefits. These results should serve evidence-based clinical practice. FUNDING: UK National Institute for Health Research Oxford Health Biomedical Research Centre.

Overview

CoChat Summary

## TL;DR

This systematic review and network meta-analysis included 170 RCTs (47,950 participants) of 36 pharmacological treatments for adults with insomnia disorder, with 154 double-blind RCTs (44,089 participants) eligible for the network meta-analysis. Overall, eszopiclone and lemborexant had the most favorable profiles, while benzodiazepines were effective short term but had less favorable tolerability and safety, and long-term evidence was sparse.

## Key findings

  • The review included 170 trials (36 interventions, 47,950 participants); 154 double-blind RCTs (30 interventions, 44,089 participants) were eligible for network meta-analysis.
  • In acute treatment, benzodiazepines, doxylamine, eszopiclone, lemborexant, seltorexant, zolpidem, and zopiclone were more efficacious than placebo, with SMDs 0.36–0.83 and high to moderate certainty.
  • In acute treatment, intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer all-cause discontinuations than ramelteon: OR 0.72, 0.70, and 0.71, respectively.
  • In long-term treatment, eszopiclone and lemborexant were more efficacious than placebo (SMD 0.63 and 0.41), and eszopiclone and zolpidem had fewer all-cause discontinuations than ramelteon (OR 0.43 for both).
  • Zopiclone and zolpidem caused more dropouts due to adverse events than placebo in acute treatment (OR 2.00 and 1.79), and zopiclone also had more adverse-event dropouts than eszopiclone (OR 1.82), daridorexant (3.45), and suvorexant (3.13).

## Methods

  • Systematic review and network meta-analysis of randomized controlled trials comparing pharmacological treatments or placebo as oral monotherapy for adults (≥18 years) with insomnia disorder; double-blind RCTs were used for the network meta-analysis.
  • Searched Cochrane CENTRAL, MEDLINE, PubMed, Embase, PsycINFO, WHO ICTRP, ClinicalTrials.gov, and regulatory-agency websites from database inception to Nov 25, 2021, with no language restrictions.
  • Primary outcomes were efficacy (self-rated sleep quality/satisfaction), acceptability (all-cause discontinuation), tolerability (discontinuation due to adverse events), and safety (any adverse event); analyses used random-effects pairwise and network meta-analysis, with certainty assessed using CINeMA.

## Limitations

  • The paper states that many comparisons were rated low or very low quality by CINeMA, especially at long-term timepoints, and that many trials did not report adequate information on randomisation and allocation concealment.
  • The authors state that long-term networks were mostly single-standing nodes connected only to placebo, so many active-treatment comparisons relied on indirect evidence and the untestable consistency assumption.
  • The paper states that it included only double-blind trials to improve rigor; evidence also suggests a limitation that specific adverse events were reported inconsistently, and there was very little long-term evidence for many drugs.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)00878-9

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

3 Valid · 1 Not valid · 29 Not checked · 145 Own results and interpretations

89 more claims

Create a free account to see all 178 claims and to verify the 42 references still open.

See all claims — free account
  • Probably not a substantial claim. 50
  • The quote only partly states this claim. 4
  • It may state two separate claims as one. 44

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Jaffer, 2017, Trazodone for insomnia: a systematic review, Innov Clin Neurosci, 14, 24

Cited by

See all 446

Metadata

Authors
De Crescenzo, F., D'Alò, G. L., Ostinelli, E. G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F., Del Giovane, C., Quested, D. J., Cowen, P. J., Barbui, C., Amato, L., Efthimiou, O., & Cipriani, A.
Affiliations
  • Oxford Health NHS Foundation Trust (GB)
  • University of Rome Tor Vergata (IT)
  • Soseikai General Hospital (JP)
  • Regione Lazio (IT)
  • Magna Graecia University (IT)
  • University of Verona (IT)
  • University of Bern (CH)
Corresponding author
Cipriani, Andrea
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-07
Volume
400
Issue
10347
Pages
170-184
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4285498627
Cited by
446
References
42
Citations by year
2026: 94 · 2025: 138 · 2024: 111 · 2023: 86 · 2022: 17
FWCI
12.85
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
  • Open Access CRIS of the University of Bern
Funders
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (80083)
  • NIHR Oxford Biomedical Research Centre (BRC-1215\u201320005)
  • National Institute for Health and Care Research (RP-2017-08-ST2\u2013006, RCPG 0407-10155-RISC)
  • Angelini Pharma
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
Keywords
insomnia, pharmacotherapy, benzodiazepines, eszopiclone, zolpidem, zopiclone, melatonin, ramelteon, zaleplon, doxylamine, lemborexant, treatment discontinuation, adverse events, sleep quality, long-term treatment, acute treatment, comparative effectiveness, adults
MeSH terms
Eszopiclone, Zolpidem, Adult, Benzodiazepines, Doxepin, Humans, Sleep Initiation and Maintenance Disorders, Melatonin, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00878-9
The paper
De Crescenzo, F., D'Alò, G. L., Ostinelli, E. G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F., Del Giovane, C., Quested, D. J., Cowen, P. J., Barbui, C., Amato, L., Efthimiou, O., & Cipriani, A. (2022). Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(22)00878-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.